Fortress Biotech, Inc. (NASDAQ:FBIO)

Coronado Biosciences, Inc., a clinical stage biopharmaceutical company, focuses on the development of immunotherapy biologic agents for the treatment of autoimmune diseases and cancer. Its principal pharmaceutical product candidates in clinical development include TSO or CNDO-201, which is a biologic comprising Trichuris suis ovathe, the microscopic eggs of the porcine whipworm, for the treatment of autoimmune diseases, such as Crohn’s disease, ulcerative colitis, multiple sclerosis, autism, psoriasis, type 1 diabetes, and rheumatoid arthritis; and CNDO-109, a biologic that activates the immune system’s natural killer, cells to seek and destroy cancer cells, for the treatment of acute myeloid leukemia. Coronado Biosciences, Inc. has collaboration agreement with Dr. Falk Pharma GmbH and OvaMed GmbH for the development of TSO to treat Crohn’s disease. The company was founded in 2006 and is based in Burlington, Massachusetts.

Last updated April 9, 2013